GLP-1 Drugs Like Semaglutide Could Cut Heart Disease Risk by 22% in High-Risk Adults
A large emulation study finds semaglutide-class drugs may reduce 10-year cardiovascular events by nearly 3% absolute in high-risk, obese, CVD-free adults.
Resumen
Researchers used data from over 800,000 Europeans and North Americans to model what would happen if high-risk, obese adults without existing heart disease took GLP-1 receptor agonists like semaglutide. By applying the risk factor changes seen in the SELECT trial to real-world survey populations, they projected a 22% relative reduction in 10-year cardiovascular disease incidence — translating to roughly 3 fewer events per 100 people over a decade. Men showed slightly larger absolute benefits than women, though relative reductions were similar. Benefits shrank in lower-risk or non-obese groups and when accounting for imperfect medication adherence. The findings support expanding GLP-1 therapy into primary prevention, but authors stress randomized trials are needed to confirm real-world benefit.
Resumen detallado
GLP-1 receptor agonists (GLP-1RAs) such as semaglutide have already demonstrated cardiovascular benefits in obese patients with established heart disease. But a critical unanswered question remains: can these drugs also prevent first cardiovascular events in high-risk people who haven't yet developed disease?
This study tackled that question using a trial emulation approach. Investigators built a cardiovascular risk model from 610,789 CVD-free individuals drawn from the Global Cardiovascular Risk Consortium, incorporating five key risk factors — BMI, HbA1c, systolic blood pressure, high-sensitivity CRP, and non-HDL cholesterol. They then applied the sex-specific, placebo-adjusted changes in those risk factors observed in the SELECT semaglutide trial to 200,012 individuals from two large contemporary health surveys.
Among the 21,720 survey participants with BMI ≥27 and elevated baseline cardiovascular risk (SCORE2 ≥7.5%), emulated GLP-1RA therapy reduced projected 10-year CVD incidence from 13.82% to 10.83% — an absolute reduction of 2.99% and a relative reduction of 22%. Men experienced slightly larger absolute reductions (3.14%) compared to women (2.70%), though relative risk reductions were comparable across sexes at roughly 21–23%.
Importantly, benefits were significantly attenuated in non-obese individuals and those at lower baseline cardiovascular risk, and diminished further when realistic assumptions about medication non-compliance were applied. This underscores the importance of patient selection for maximizing the preventive impact of these agents.
The study carries notable caveats — it is an emulation, not a randomized trial, and is co-funded by Novo Nordisk, the maker of semaglutide. The findings nonetheless provide a compelling quantitative rationale for dedicated primary prevention trials of GLP-1RAs in appropriately selected high-risk populations.
Hallazgos clave
- Emulated semaglutide therapy reduced 10-year CVD incidence by 22% relatively and ~3% absolutely in high-risk obese adults.
- Men showed slightly larger absolute risk reductions (3.14%) than women (2.70%), with similar relative reductions (~21–23%).
- Benefits were substantially attenuated in non-obese individuals and those with lower baseline cardiovascular risk.
- Lower medication compliance assumptions further diminished projected risk reductions.
- Results support rationale for randomized primary prevention trials of GLP-1RAs in high-risk, obese populations.
Metodología
The study used a trial emulation design, fitting a 10-year CVD risk model on 610,789 CVD-free individuals from the Global Cardiovascular Risk Consortium, then applying sex-stratified, placebo-adjusted risk factor changes from the SELECT RCT to 200,012 individuals in two contemporary health examination surveys. Primary analyses focused on individuals with BMI ≥27 and SCORE2-derived baseline risk ≥7.5%.
Limitaciones del estudio
This is a modeled emulation rather than a randomized controlled trial, so causal inference is limited. The study was co-funded by Novo Nordisk via an unrestricted grant, introducing potential funding bias despite reported independence. Risk factor changes were borrowed from a trial population that may not perfectly match general survey populations.
¿Te ha gustado este resumen?
Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.
Introduce tu correo electrónico para suscribirte: